[Hyperthermic intraperitoneal chemotherapy in the German DRG system. Analysis of case cost calculations of a maximum care university].
BACKGROUND
Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) offers patients with peritoneal cancer of various origins the chance of a relevant increase in life expectancy. These cases are very complex from a medical viewpoint and very expensive from an economical aspect. An analysis of case cost calculations was performed to find out whether this procedure can on average be carried out cost-effectively by a maximum care university.


METHODS
All cases from 2008 in which HIPEC was carried out were analyzed. The types of main diagnosis, secondary diagnoses, procedures, times from incision to suture and hospital stay were analyzed. On the basis of the case costs the proceeds and marginal returns were calculated from the diagnosis-related groups (DRGs) and additional remuneration when applicable. The causes of positive and negative marginal returns were explained using the InEK cost matrix.


RESULTS
In 18 patients there were 9 different main diagnoses and 7 different "main procedures" (from a surgical perspective the most resource intensive procedures) and a total of 10 different DRGs were identified in the grouping algorithm. With an average of 2 operations (range 1-7) per patient the summed incision-to-suture time was 423 min (170-962 min). The patients stayed on average 6.4 days (1.3-17.6 days) in intensive care. The average case cost was 21,072€ (range 8,657-55,904€) and the proceeds 20,474€ (6,333-37,497€). Each case had on average a debit balance of 598€ (range from 11,843€ profit balance to 18,407€ debit balance) with an assumed base rate of 2,786€. The causes for positive or negative marginal profits were mostly operating times, incision-to-suture times and duration of intensive care.


CONCLUSIONS
The proceeds showed on average a deficit of only 3% compared to the costs. The operating times must be decreased by optimization particularly of the preoperative approach. Interventions should be carried out in one stage only and the intraoperative connecting and waiting times should be reduced in order to reduce the incision-to-suture times.
Kilian
M
M
Klinik für Allgemein-, Visceral-, Gefäss- und Thoraxchirurgie, Charité-Universitätsmedizin Berlin, Deutschland. maik.kilian@charite.de
Hammerich
R
R
Langelotz
C
C
Raue
W
W
Tsilimparis
N
N
Rau
B
B
Hartmann
J
J
D000328:Adult; D000368:Aged; D010478:Chemotherapy, Cancer, Regional Perfusion / Q000191:economics*; D003362:Cost-Benefit Analysis; D003953:Diagnosis-Related Groups / Q000191:economics*; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy / Q000191:economics; D005858:Germany; D006801:Humans; D006979:Hyperthermia, Induced / Q000191:economics*; D007263:Infusions, Parenteral / Q000191:economics; D008297:Male; D008875:Middle Aged; D009313:National Health Programs / Q000191:economics*; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000191:economics; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000191:economics* / Q000401:mortality / Q000556:secondary; D015996:Survival Rate